Here we sought to characterize the repertoire of somatic genetic alterations of breast cancers from pathogenic PALB2 germline mutation carriers using a combination of whole-exome and targeted massively parallel sequencing to define whether bi-allelic PALB2 inactivation is present in these tumors. The gene discussed is PALB2; the disease is breast carcinoma.